2,4-dinitroanisole

Developmental toxicity / teratogenicity

Administrative data

Endpoint:

developmental toxicity

Type of information:

experimental study

Adequacy of study:

key study

Study period:

21 November 2017 - 22 August 2018

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

guideline study

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

2018

Report date:

2018

Materials and methods

Test guideline

Qualifier:

according to guideline

Guideline:

other: - OECD 421 Guideline for testing of chemicals adopted 29.07.16: Reproduction/developmental toxicity screening test.

Deviations:

no

GLP compliance:

yes (incl. QA statement)

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

2,4-dinitroanisole

EC Number:

204-310-9

EC Name:

2,4-dinitroanisole

Cas Number:

119-27-7

Molecular formula:

C7H6N2O5

IUPAC Name:

2,4-dinitroanisole

Specific details on test material used for the study:

- Physical form / colour: Pale yellow/solid
- Batch number: 55503625
- Lot number: 02/13
- Purity: 100 %
- Storage conditions: At room temperature in the dark

Test animals

Species:

rat

Strain:

Wistar

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Source: Charles River
- Females nulliparous and non-pregnant: no
- Age at study initiation: Males: 8 to 10 weeks, Females: 10 to 13 weeks
- Weight at study initiation: Males: 235-348 g, Females: 192-231 g
- Fasting period before study: none
- Housing:
Cages with standard, granulated, S8-15 sawdust bedding (J. Rettenmaier & Söhne)
Premating period (5 animals/cage) Makrolon type IV cages
Mating period (one male and one female/cage) Makrolon type III cages
Postmating, gestation and lactation periods (individual) Makrolon type III cages
- Use of restrainers for preventing ingestion (if dermal): n/a
- Diet: ad libitum
- Water: ad libitum
- Acclimation period: Eight days between arrival and pre-treatment start. After acclimatization period,
the animals were subjected to a 19-day pretest period.

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20-24
- Humidity (%): 30 and 70
- Air changes (per hr): 15-20
- Photoperiod (hrs dark / hrs light): 12 hours fluorescent light/12 hours dark.
IN-LIFE DATES: From: 21 February 2018 To: 22 August 2018

Administration / exposure

Route of administration:

oral: gavage

Vehicle:

arachis oil

Details on exposure:

PREPARATION OF DOSING SOLUTIONS:
Prepared weekly in Arachis oil and stored at room
temperature and in the dark
DIET PREPARATION
- Rate of preparation of diet (frequency): standard Teklad 2014C rat/mouse maintenance diet used
- Mixing appropriate amounts with (Type of food): n/a
- Storage temperature of food: not specified
VEHICLE
- Justification for use and choice of vehicle (if other than water): Standard vehicle in these studies
- Concentration in vehicle: n/a
- Amount of vehicle (if gavage): 5mL/Kg
- Lot/batch no. (if required): KMO9422, KMO9047
- Purity: not specified

Analytical verification of doses or concentrations:

yes

Details on analytical verification of doses or concentrations:

The formulations prepared at three different concentrations were analyzed twice over the course of
the study to verify that they were correctly prepared. Controls were also analysed to confirm the ab
sence of the test item.
The test item was used as analytical standard.
12-mL aliquots (in duplicate) were taken from each formulation to be analysed.

Details on mating procedure:

- M/F ratio per cage: 1:1
- Length of cohabitation: Up to 2 weeks
- Proof of pregnancy: vaginal plug and (or) sperm in vaginal smear
- After 14 days of unsuccessful pairing replacement of first male by another male with proven fertility.
- Further matings after two unsuccessful attempts: not specified
- After successful mating each pregnant female was caged: Females were separated when evidence
of mating was detected
- Any other deviations from standard protocol: not specified

Duration of treatment / exposure:

5-8 weeks

Frequency of treatment:

Once daily

Doses / concentrations

Doses / concentrations 1

Dose / conc.:

0 mg/kg bw/day (nominal)

Remarks:

Group 1 (control)

Doses / concentrations 2

Dose / conc.:

1 mg/kg bw/day (nominal)

Remarks:

Group 2

Doses / concentrations 3

Dose / conc.:

5 mg/kg bw/day (nominal)

Remarks:

Group 3

Doses / concentrations 4

Dose / conc.:

20 mg/kg bw/day (nominal)

Remarks:

Group 4

No. of animals per sex per dose:

10 males and 10 females

Control animals:

yes, concurrent vehicle

Details on study design:

- Dose selection rationale: Based on the results of GLP Toxicology Study No. 87-XE-ODBP-10
conducted by the U.S. Army Public Health Command and the preliminary results obtained in the
previous non-GLP study PX87XC 7-day Oral (Gavage) Dose-Range Toxicity Study for OECD 421
conducted at Envigo CRS, S.A.U.
- The high dose level of 20 mg/kg was chosen with the aim of inducing some developmental and/or
maternal toxicity but not death or severe suffering. This dose level was previously tested in toxicology
study No. 87-XE-ODBP-10 and produced signs of systemic toxicity but no mortality or suffering. In
study PX87XC this dose level showed no evidence of toxicity or mortality.
- The intermediate and low dose levels were selected as a descending sequence to demonstrate any
possible exposure-related response.
- Rationale for animal assignment: Random

Examinations

Statistics:

Bartlett's test, Williams' test, Dunnetts test.
Linear-by-linear test (Cytel, 1995).
Cochran-Armitage test (Cytel, 1995).

Indices:

Reproductive indices: Estrous cycle, pre-coital interval, mating performance, fertility and gestation length.
Offspring viability indices: Survival indexes, litter size, sex ratio, body weight, clinical signs, ano-genital distances or external examination.

Results and discussion

Results: maternal animals

General toxicity (maternal animals)

Clinical signs:

no effects observed

Dermal irritation (if dermal study):

not examined

Mortality:

mortality observed, non-treatment-related

Description (incidence):

The death of two females (numbers 75 and 66) could be considered occasional and not treatment related given that no mortality was recorded at the high dose, due to the incidence observed in the study and to the fact that no test item related effects were observed in these animals during the study. The major factor contributing to their death remained undetermined histologically.

Body weight and weight changes:

no effects observed

Food consumption and compound intake (if feeding study):

no effects observed

Food efficiency:

not examined

Water consumption and compound intake (if drinking water study):

not examined

Ophthalmological findings:

not examined

Haematological findings:

not examined

Clinical biochemistry findings:

effects observed, treatment-related

Description (incidence and severity):

T4 and TSH determinations: a decrease was recorded when compared to Control in adult males (at all doses but mainly at 20 mg/kg/day) and females (at 20 mg/kg/day). It was also observed at 20 mg/ kg/day in offspring males and females on Day 13 of lactation. Despite the effect observed at 20 mg/ kg/day in T4 and TSH determinations, thyroid and parathyroid glands weights were unaffected by treatment. Based on the fact that what was recorded was a decrease in the levels of TSH analyzed and not an increase (which would be related to a possible effect attributable to the components that alter the hormonal function at the level of generation of hypertrophy / follicular hyperplasia) and that no macroscopic findings have been recorded in the pituitary or thyroid / parathyroid glands, this finding cannot be considered as a relevant adverse effect.

Urinalysis findings:

not examined

Behaviour (functional findings):

not examined

Immunological findings:

not examined

Organ weight findings including organ / body weight ratios:

effects observed, treatment-related

Description (incidence and severity):

Body-weight-adjusted prostate, seminal vesicles and coagulating gland and spleen weights in males from Group 4 (20 mg/kg/day), epididymides in males from Groups 3 and 4 (5 and 20 mg/kg/day, respectively) and brain weight in females from Group 4 (20 mg/kg/day) differed significantly when compared to control.

Gross pathological findings:

no effects observed

Neuropathological findings:

no effects observed

Histopathological findings: non-neoplastic:

no effects observed

Histopathological findings: neoplastic:

not examined

Other effects:

not examined

Description (incidence and severity):

During treatment one female at 1 mg/kg/day (number 62) and one at 5 mg/kg/day (number 76) showed irregular cycles and one female administered at 5 mg/kg/day (number 70) was acyclic. At termination, all reproductive phase females (pregnant) showed diestrus with the exception of 1/9
(number 68) at 1 mg/kg/day and 2/9 (numbers 70 and 71) at 5 mg/kg/day. These females showed different stages of estrous cycle, which indicated they had recovered the cycle.

Details on results:

There was no effect of treatment on the pre-coital interval: all animals mated within four days of mating at the first estrous, with the exception of one female at 5 mg/kg/day, whose pre-coital interval extended to 14 days of mating with one male and 2 days of mating with a second male.
Mating performance was 100% for all groups except 5 mg/kg/day males, for which it was 90%. Fertility was 100% at 0 and 20 mg/kg/day and 90% (9/10) at 1 and 5 mg/kg/day for males and females. These differences cannot be taken into account based on occurrence and lack of dose response.
Gestation length was within the normal range in all treated groups.

Maternal developmental toxicity

Number of abortions:

not specified

Pre- and post-implantation loss:

not specified

Total litter losses by resorption:

not specified

Early or late resorptions:

not specified

Dead fetuses:

not specified

Changes in pregnancy duration:

not specified

Changes in number of pregnant:

not specified

Other effects:

not specified

Effect levels (maternal animals)

Key result

Dose descriptor:

NOAEL

Effect level:

ca. 20 mg/kg bw/day (nominal)

Based on:

test mat.

Remarks on result:

other: No effects seen in any of the parameters tested

Results (fetuses)

Fetal body weight changes:

no effects observed

Changes in sex ratio:

not specified

Changes in litter size and weights:

not specified

Changes in postnatal survival:

not specified

External malformations:

not specified

Skeletal malformations:

not specified

Visceral malformations:

not specified

Other effects:

not specified

Effect levels (fetuses)

Key result

Dose descriptor:

NOAEL

Effect level:

ca. 20 mg/kg bw/day (nominal)

Based on:

test mat.

Sex:

male/female

Remarks on result:

other: No effects seen in any of the parameters tested

Overall developmental toxicity

Key result

Developmental effects observed:

no

Any other information on results incl. tables

There was no effect on offspring growth. There were no offspring clinical or necropsy signs observed which were indicative of a reaction to DNAN, and there was no relevant effect on litter size, sex ratio, survival indices, body weights, ano-genital distance or nipple areolae.

Applicant's summary and conclusion

Conclusions:

The No Observed Adverse Effect Level (NOAEL) for reproductive / developmental toxicity was considered to be 20 mg/kg/day, taking into account that there was no effect on estrous cycle, pre-coital interval, mating performance, fertility and gestation length or in the offspring on survival indexes, litter size, sex ratio, body weight, clinical signs, ano-genital distances or external examination.